Novel drug shuts down master protein key to lymphoma

ScienceDaily - Health and Medicine News

Researchers have discovered how an experimental drug is capable of completely eradicating human lymphoma in mice after just five doses. The study sets the stage for testing the drug in clinical trials of diffuse large B-cell lymphoma, the most common subtype of non-Hodgkin lymphoma, itself the seventh most frequently diagnosed cancer in the US.